120
Participants
Start Date
October 16, 2023
Primary Completion Date
April 26, 2026
Study Completion Date
October 26, 2028
TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
PD-1 inhibitor
Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
Consolidation Radiation
IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
Salvage Radiation
IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
RECRUITING
Cancer hospital, CAMS, Beijing
Peking University Cancer Hospital & Institute
OTHER
Hebei Medical University Fourth Hospital
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Anyang Tumor Hospital
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER